# **Conference Program**

# Saturday, October 17

7:00 p.m.-8:30 p.m. Welcome and Keynote Lectures

Grand Ballroom E-K

Session Chairperson: Jane E. Visvader, Walter and Eliza Hall Institute of Medical

Research, Parkville, Australia

Potential applications of genomics in patients with metastatic breast cancer

Fabrice Andre, Institut Gustave-Roussy, Villejuif, France

Harnessing genetic dependencies in cancer therapy

Alan Ashworth, University of California, San Francisco, CA

8:30 p.m.-10:00 p.m. Opening Reception

Grand Ballroom Foyer

**Sunday, October 18** 

7:30 a.m.-8:30 a.m. Continental Breakfast

Grand Ballroom Foyer

8:30 a.m.-10:30 a.m. Plenary Session 1: Genomics - Sporadic and Hereditary

Grand Ballroom E-K

Session Chairperson: Charles M. Perou, Lineberger Comprehensive Cancer Center,

UNC School of Medicine, Chapel Hill, NC

Molecular classification of breast tumors based on multiplatform analysis

Charles M. Perou

A compendium of 560 whole-genome sequenced breast cancers

Serena Nik-Zainal, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Genetic determinants of breast cancer risk

Douglas Easton, University of Cambridge, Cambridge, United Kingdom

Spatial systems biology of cancer

Joe W. Gray, Oregon Health and Science University, Portland, OR

10:30 a.m.-11:00 a.m. Break

Grand Ballroom Foyer

#### 11:00 a.m.-1:00 p.m. Plenary Session 2: The Differentiation Hierarchy and Cancer

Grand Ballroom E-K

Session Chairperson: Jane E. Visvader, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

#### Using the breast epithelial hierarchy to dissect tumor heterogeneity

Jane E. Visvader

# Developmental insights into breast cancer intratumoral heterogeneity

Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX

#### Protein C receptor as a surface marker of mammary stem cells and its implication in breast cancer

Yi Arial Zeng, Shangai Institute of Biochemistry and Cell Biology, Shanghai, China

#### Sox10 regulates stem/progenitor and mesenchymal cell states in mammary epithelial cells

Christopher Dravis, Salk Institute for Biological Studies, La Jolla, CA

# 1:15 p.m.-1:45 p.m. Short Talks from Proffered Papers

Grand Ballroom E-K

Session Chairperson: Thomas (Trey) F. Westbrook, Baylor College of Medicine,

Houston, TX

#### Understanding the role of BCL11A in triple-negative breast cancer\*

Walid T. Khaled, University of Cambridge, Cambridge, United Kingdom

#### The spliceosome is a therapeutic vulnerability in MYC-driven breast cancer\*

Tiffany Hsu, Baylor College of Medicine, Houston, TX

# GLUT1 is required for induction of mammary tumorigenesis by activated ErbB2/HER2/Neu\*

Steven M. Anderson, University of Colorado Anschutz Medical Campus, Aurora, CO

#### 1:45 p.m.-4:15 p.m. Poster Session A with Lunch

Grand Ballroom A-D

#### 4:30 p.m.-6:00 p.m. Plenary Session 3: Breast Tumor Heterogeneity (Intratumor and Intertumoral)

Grand Ballroom E-K

Session Chairperson: Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center,

New York, NY

#### Functional and clinical relevance of intratumor heterogeneity in breast

Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA

#### Clonal analysis of the in vivo growth of normal and de novo transformed human mammary cells

Connie J. Eaves, BC Cancer Agency/Terry Fox Laboratory, Vancouver, BC, Canada

# Breast cancer inter- and intratumor genetic heterogeneity

Jorge S. Reis-Filho

# 6:00 p.m.- Evening Off/Dinner on Own

\*Short talks from proffered papers

# Monday, October 19

7:30 a.m.-8:30 a.m. Continental Breakfast

Grand Ballroom Foyer

8:30 a.m.-10:30 a.m. Plenary Session 4: Tumor Microenvironment and Immunotherapy

Grand Ballroom E-K

Session Chairperson: Valerie M. Weaver, University of California Medical Center, San

Francisco, CA

# Tissue tension programs tumor aggression

Valerie M. Weaver

# Immune control of breast cancer metastasis

Alana L. Welm, Oklahoma Medical Research Foundation, Oklahoma City, OK

#### Importance of anti-host immunity for breast cancer patients

Sherene Loi, Peter MacCallum Cancer Center, Camberwell, Australia

#### Personalized immunotherapy

Naiyer Rizvi, Columbia University, New York, NY

10:30 a.m.-11:00 a.m. Break

Grand Ballroom Foyer

11:00 a.m.-1:00 p.m. Plenary Session 5: Animal Models and Their Applications

Grand Ballroom E-K

Session Chairperson: Elaine R. Mardis, Washington University School of Medicine, St.

Louis, MO

# Development of targeted therapeutics using patient-derived xenografts

Michael T. Lewis, Baylor College of Medicine Cancer Center, Houston, TX

#### Targeting the BCL-2 family in breast cancer

Geoffrey J. Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

#### Genomics of a STAT1 knockout mouse model of human ER+ breast cancer

Elaine R. Mardis

#### Modeling and targeting RB-deficiency in triple-negative breast cancer

Eldad Zacksenhaus, Toronto General Hospital, Toronto, ON, Canada

1:00 p.m.-3:00 p.m. Free Time/Lunch on Own

# 3:00 p.m.-5:00 p.m. Plenary Session 6: Monitoring Metastasis and CTCs

Grand Ballroom E-K

Session Chairperson: Nicholas C. Turner, Institute of Cancer Research, Breakthrough Breast Cancer Research Center, London, United Kingdom

#### Circulating tumor DNA and prediction of relapse in early breast cancer

Nicholas C. Turner

# Circulating tumor cells, prognosis in metastatic breast cancer, and the SWOG S0500 study

Jeffrey B. Smerage, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

#### A stem cell program in early human metastatic breast cancer cells

Zena Werb, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

#### Deep sequencing of circulating tumor DNA for personalized cancer detection and monitoring

Maximilian Diehn, Stanford University, Stanford, CA

# 5:00 p.m.-5:30 p.m. Short Talks from Proffered Papers

Grand Ballroom E-K

Session Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX

#### Tissue tension promotes mammary stemness and breast cancer aggression\*

Jason J. Northey, University of California, San Francisco, CA

# The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ\*

Michalina Janiszewska, Dana-Farber Cancer Institute, Boston, MA

# Modeling the tumor microenvironment to identify novel loss of function mutations in breast cancer progression\*

Racheal Natrajan, The Institute of Cancer Research, London, United Kingdom

5:30 p.m.-7:30 p.m. Poster Session B/Reception

Grand Ballroom A-D

<sup>\*</sup>Short talks from proffered papers

# **Tuesday, October 20**

7:30 a.m.-8:30 a.m. Continental Breakfast

Grand Ballroom Fover

8:30 a.m.-10:00 a.m. Plenary Session 7: Targeted Therapies in Luminal Breast Cancer

Grand Ballroom E-K

Session Chairperson: Matthew J. Ellis, Lester and Sue Smith Breast Center, Baylor

College of Medicine, Houston, TX

# Identifying and prioritizing targets in ER+ breast cancer

Matthew J. Ellis

# PI3K/AKT/TOR pathway: Therapeutic targeting and role in breast cancer progression

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

# Targeting cyclin-dependent kinases in breast cancer

Richard S. Finn, University of California, Los Angeles, CA

10:00 a.m.-10:15 a.m. Break

Grand Ballroom Foyer

10:15 a.m.-11:45 a.m. Plenary Session 8: New Omics in Breast Cancer

Grand Ballroom E-K

Session Chairperson: Gary L. Johnson, University of North Carolina School of

Medicine, Chapel Hill, NC

#### Proteogenomic and phosphoproteomic analysis of human breast cancer

Philipp Mertins, The Broad Institute of MIT and Harvard, Cambridge, MA

# Insights into metabolome of breast cancer

Arun Sreekumar, Baylor College of Medicine, Houston, TX

# Resiliency of the breast cancer kinome to targeted kinase inhibition

Gary L. Johnson

11:45 a.m. Departure